CL2013002810A1 - Composicion farmaceutica solida oral que comprende a) un compuesto 2-amino-2-[2-(4-octil-fenil)-etil]-propano-1,3-diol (fingolimod) en una cantidad de 0,5 mg o menos, o una sal del mismo, b) un relleno y c) un estabilizante que comprende una ciclodextrina; y su uso para tratar una enfermedad autoinmune tal como esclerosis multiple. - Google Patents

Composicion farmaceutica solida oral que comprende a) un compuesto 2-amino-2-[2-(4-octil-fenil)-etil]-propano-1,3-diol (fingolimod) en una cantidad de 0,5 mg o menos, o una sal del mismo, b) un relleno y c) un estabilizante que comprende una ciclodextrina; y su uso para tratar una enfermedad autoinmune tal como esclerosis multiple.

Info

Publication number
CL2013002810A1
CL2013002810A1 CL2013002810A CL2013002810A CL2013002810A1 CL 2013002810 A1 CL2013002810 A1 CL 2013002810A1 CL 2013002810 A CL2013002810 A CL 2013002810A CL 2013002810 A CL2013002810 A CL 2013002810A CL 2013002810 A1 CL2013002810 A1 CL 2013002810A1
Authority
CL
Chile
Prior art keywords
cyclodextrin
fingolimod
diol
octyl
propane
Prior art date
Application number
CL2013002810A
Other languages
English (en)
Inventor
Supriya Rane
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45953284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013002810(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2013002810A1 publication Critical patent/CL2013002810A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)

Abstract

La solicitud 201302810 describe a una composición farmacéutica sólida oral que comprende a) un compuesto seleccionado a partir de 2-amino-2-[2-(4-octil-fenil)-etil]-propano-1,3-diol (fingolimod), o una sal farmacéuticamente aceptable del mismo, y un derivado de fosfato del mismo, b) un relleno, y c) un estabilizante que comprende una ciclodextrina o un derivado de la misma, en donde la ciclodextrina o derivado de la misma es una ciclodextrina natural, una ciclodextrina ramificada, una alquil-ciclodextrina o una hidroxalquil-ciclodextrina; y el uso de la composición para preparar un medicamento útil para el tratamiento de una enfermedad autoinmune.
CL2013002810A 2011-04-01 2013-09-30 Composicion farmaceutica solida oral que comprende a) un compuesto 2-amino-2-[2-(4-octil-fenil)-etil]-propano-1,3-diol (fingolimod) en una cantidad de 0,5 mg o menos, o una sal del mismo, b) un relleno y c) un estabilizante que comprende una ciclodextrina; y su uso para tratar una enfermedad autoinmune tal como esclerosis multiple. CL2013002810A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161470747P 2011-04-01 2011-04-01
US201161545835P 2011-10-11 2011-10-11

Publications (1)

Publication Number Publication Date
CL2013002810A1 true CL2013002810A1 (es) 2014-02-14

Family

ID=45953284

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013002810A CL2013002810A1 (es) 2011-04-01 2013-09-30 Composicion farmaceutica solida oral que comprende a) un compuesto 2-amino-2-[2-(4-octil-fenil)-etil]-propano-1,3-diol (fingolimod) en una cantidad de 0,5 mg o menos, o una sal del mismo, b) un relleno y c) un estabilizante que comprende una ciclodextrina; y su uso para tratar una enfermedad autoinmune tal como esclerosis multiple.

Country Status (35)

Country Link
US (5) US9592208B2 (es)
EP (2) EP2694037B1 (es)
JP (1) JP6019101B2 (es)
KR (1) KR102027014B1 (es)
CN (1) CN103476400B (es)
AR (1) AR085749A1 (es)
AU (1) AU2012236357B2 (es)
BR (1) BR112013024430B1 (es)
CA (1) CA2831600C (es)
CL (1) CL2013002810A1 (es)
CO (1) CO6771459A2 (es)
CY (2) CY1118423T1 (es)
DK (2) DK2694037T3 (es)
EA (2) EA027721B1 (es)
EC (1) ECSP13012912A (es)
ES (2) ES2610966T3 (es)
GT (1) GT201300227A (es)
HK (1) HK1190309A1 (es)
HR (2) HRP20170021T1 (es)
HU (1) HUE031286T2 (es)
IL (1) IL228250B (es)
JO (1) JO3177B1 (es)
LT (2) LT2694037T (es)
MA (1) MA34981B1 (es)
MX (1) MX342522B (es)
MY (2) MY163746A (es)
PE (2) PE20170913A1 (es)
PL (2) PL2694037T3 (es)
PT (2) PT2694037T (es)
RS (1) RS59917B1 (es)
SG (1) SG193256A1 (es)
SI (2) SI3143990T1 (es)
TW (1) TWI528958B (es)
WO (1) WO2012135561A1 (es)
ZA (1) ZA201306636B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014141298A2 (en) * 2013-03-11 2014-09-18 Astron Research Limited Stable pharmaceutical composition of fingolimod
CN103222966A (zh) * 2013-04-01 2013-07-31 北京万全德众医药生物技术有限公司 一种含有盐酸芬戈莫德的固体药物组合物及其制备方法
US20160128951A1 (en) * 2013-07-29 2016-05-12 Aizant Drug Research Solutions Pvt Ltd Pharmaceutical compositions of fingolimod
WO2016026461A1 (en) * 2014-08-22 2016-02-25 Sunshine Lake Pharma Co., Ltd. Solid composition of fingolimod and preparation thereof
WO2016042493A1 (en) 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
EP3247341A4 (en) * 2015-01-20 2018-12-19 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
WO2018178744A1 (en) 2017-03-29 2018-10-04 Deva Holding Anonim Sirketi Stable formulations of fingolimod
WO2021158848A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Dosage regimen of an s1p receptor agonist
WO2021158838A1 (en) 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Dosage regimen of an s1p receptor modulator

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
ES2126658T3 (es) 1992-10-21 1999-04-01 Yoshitomi Pharmaceutical Compuesto de 2-amino-1,3-propanodiol e inmunosupresor.
CZ285953B6 (cs) 1995-12-28 1999-12-15 Yoshitomi Pharmaceutical Industries, Ltd. Vnější přípravek pro topické podání
JPH11209277A (ja) * 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
US6476004B1 (en) 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
GB9624038D0 (en) 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
DK0990440T3 (da) 1997-02-27 2009-02-23 Novartis Ag Farmaceutisk sammensætning indeholdende 2-amino-2[2-(4-octylphenyl)-ethyl]-propan-1,3-diol, en lecithin og et saccharid
AU735853B2 (en) 1997-04-04 2001-07-19 Mitsubishi Pharma Corporation 2-aminopropane-1,3-diol compound, Pharmaceutical use thereof and synthetic intermediates therefor
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JP4627356B2 (ja) 1999-06-30 2011-02-09 松森　　昭 ウイルス性心筋炎の予防または治療薬剤
CA2421893A1 (en) 2000-08-31 2002-03-07 Merck And Co., Inc. Phosphate derivatives as immunoregulatory agents
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
US20040048877A1 (en) * 2002-05-22 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions containing flibanserin
CN1767819B (zh) 2003-04-08 2010-07-28 诺瓦提斯公司 包含s1p受体激动剂和糖醇的固体药物组合物
US20050090520A1 (en) * 2003-09-12 2005-04-28 Per Lindquist Treatment of disease or injury of the nervous system with FTY720
JP2008522977A (ja) 2004-12-06 2008-07-03 ユニバーシティ オブ バージニア パテント ファンデーション スフィンゴシン＝１−リン酸のアリールアミドアナログ
GB0502358D0 (en) * 2005-02-04 2005-03-16 Novartis Ag Organic compounds
GT200600350A (es) 2005-08-09 2007-03-28 Formulaciones líquidas
TWI389683B (zh) 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
JP2010504364A (ja) * 2006-09-26 2010-02-12 ノバルティス アーゲー Ｓ１ｐ調節剤を含む医薬組成物
TW200838497A (en) 2006-12-21 2008-10-01 Abbott Lab Sphingosine-1-phosphate receptor agonist and antagonist compounds
EP3120833A1 (en) 2007-10-12 2017-01-25 Novartis Ag Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
EP2358660A2 (en) 2008-11-11 2011-08-24 Novartis AG Salts of fingolimod
EP2907511A1 (en) 2008-12-22 2015-08-19 Novartis AG Dosage regimen for a s1p receptor agonist

Also Published As

Publication number Publication date
SI2694037T1 (sl) 2017-01-31
AU2012236357A1 (en) 2013-10-10
BR112013024430A2 (pt) 2016-12-20
EA027721B1 (ru) 2017-08-31
HRP20200249T1 (hr) 2020-05-15
US20170135967A1 (en) 2017-05-18
LT3143990T (lt) 2020-02-25
MX342522B (es) 2016-10-03
GT201300227A (es) 2015-05-05
CY1122868T1 (el) 2021-05-05
US20190247335A1 (en) 2019-08-15
CN103476400B (zh) 2016-11-09
BR112013024430B1 (pt) 2022-02-08
ECSP13012912A (es) 2013-11-29
TW201244711A (en) 2012-11-16
NZ615023A (en) 2016-07-29
EP2694037B1 (en) 2016-10-12
MY175633A (en) 2020-07-02
LT2694037T (lt) 2017-01-10
JP6019101B2 (ja) 2016-11-02
HK1190309A1 (zh) 2014-07-04
HUE031286T2 (hu) 2017-06-28
US20180193291A1 (en) 2018-07-12
JP2014509652A (ja) 2014-04-21
ES2610966T3 (es) 2017-05-04
US20140371323A1 (en) 2014-12-18
MX2013011415A (es) 2013-12-09
CO6771459A2 (es) 2013-10-15
WO2012135561A1 (en) 2012-10-04
IL228250B (en) 2020-09-30
CA2831600A1 (en) 2012-10-04
ES2773482T3 (es) 2020-07-13
US20200276137A1 (en) 2020-09-03
PE20140162A1 (es) 2014-02-12
DK2694037T3 (en) 2017-01-16
CA2831600C (en) 2020-04-21
EA201790436A3 (ru) 2018-03-30
EA201391442A1 (ru) 2014-04-30
CN103476400A (zh) 2013-12-25
US9592208B2 (en) 2017-03-14
PL3143990T3 (pl) 2020-05-18
KR20140014194A (ko) 2014-02-05
RS59917B1 (sr) 2020-03-31
AR085749A1 (es) 2013-10-23
EP3143990A1 (en) 2017-03-22
HRP20170021T1 (hr) 2017-03-10
EA035686B1 (ru) 2020-07-27
CY1118423T1 (el) 2017-06-28
SI3143990T1 (sl) 2020-03-31
JO3177B1 (ar) 2018-03-08
MA34981B1 (fr) 2014-03-01
PE20170913A1 (es) 2017-07-12
PT3143990T (pt) 2020-03-04
ZA201306636B (en) 2014-05-28
EA201790436A2 (ru) 2017-10-31
AU2012236357B2 (en) 2016-03-10
MY163746A (en) 2017-10-31
SG193256A1 (en) 2013-10-30
DK3143990T3 (da) 2020-03-02
EP2694037A1 (en) 2014-02-12
KR102027014B1 (ko) 2019-09-30
EP3143990B1 (en) 2019-11-27
TWI528958B (zh) 2016-04-11
PT2694037T (pt) 2017-01-17
PL2694037T3 (pl) 2017-05-31

Similar Documents

Publication Publication Date Title
CL2013002810A1 (es) Composicion farmaceutica solida oral que comprende a) un compuesto 2-amino-2-[2-(4-octil-fenil)-etil]-propano-1,3-diol (fingolimod) en una cantidad de 0,5 mg o menos, o una sal del mismo, b) un relleno y c) un estabilizante que comprende una ciclodextrina; y su uso para tratar una enfermedad autoinmune tal como esclerosis multiple.
PE20170302A1 (es) Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
BR112012023021A2 (pt) compostos de indazol e seus usos
CL2011001529A1 (es) Uso de un modulador o agonista de los receptores s1p derivado de 2-amino-propan-1,3-diol o 2-amino-propanol para tratar una enfermedad cronica larga en un sujeto, de manera de conseguir una disminucion diaria en la frecuencia cardiaca de 2 latidos/minutos o menos; y kit que lo comprende.
BR112012009376A2 (pt) composição farmacêutica, forma de dosagem farmacêutica, processo para a sua preparação, métodos de tratamento e seu uso
BR112014010291A2 (pt) composições de lipossoma combinacionais para terapia de câncer
CR11724A (es) Agente para tratar enfermedades
BR112013022495A2 (pt) formulação farmacêutica aquosa de tapentadol para administração oral
EA201692506A3 (ru) Ингибиторы репликации вирусов гриппа
PE20142353A1 (es) Ansolvatos de sal de noribogaina
UA113165C2 (xx) Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат
BR112013028534A2 (pt) compostos tricíclicos parcialmente saturados e métodos para produção e utilização dos mesmos
AR090601A1 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos
AR065392A1 (es) Metodos para el tratamiento por inhalacion de una enfermedad o estado respiratorio
AR091706A1 (es) Formulaciones de laquinimod sin agentes alcalinizantes
AR092993A1 (es) Laquinimod para reducir el daño talamico en la esclerosis multiple
CR20140005A (es) Una nueva composición terapéutica que contiene apomorfina como principio activo
CO6280474A2 (es) Composicion farmaceutica para el tratamiento de la eyaculacion precoz
CO7170176A2 (es) Nuevo compuesto que tiene la capacidad para inhibir la enzima deshidrogenasa11b-hidroxiesteroide tipo 1(11b-hsd1) o sal farmaceúticamente aceptable del mismo, método para producir el mismo, y composición farmaceútica que contiene el mismo como ingrediente activo
UY33453A (es) Método para el tratamiento de la hipertensión pulmonar mediante el uso de ranozalina
AR088453A1 (es) Regimen de dosificacion del agonista o modulador del receptor de s1p
CO7310521A2 (es) Composición farmaceútica que tiene fluidez mejorada, agente medicional, y método para la producción y uso del mismo
BR112013029790A2 (pt) composição farmacêutica compreendendo cetoprofeno
UY33468A (es) Agente terapeutico de liberacion sostenida para la hipertension y la disfunción renal
AR124661A2 (es) Formulaciones